1122
Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy.
 ( adverse event: develop ,  Slow acetylators: Subject, Slow acetylators: Subject.Disorder, clinical and biochemical features of phenytoin toxicity: Effect, phenytoin: Treatment, together with antituberculosis: Treatment, antituberculosis: Treatment.Drug, phenytoin: Treatment.Drug, phenytoin: Combination.Drug, antituberculosis: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: develop ,  Slow acetylators: Subject, Slow acetylators: Subject.Disorder, clinical and biochemical features of phenytoin toxicity: Effect, phenytoin: Treatment, together with antituberculosis: Treatment, antituberculosis: Treatment.Drug, phenytoin: Treatment.Drug, phenytoin: Combination.Drug, antituberculosis: Combination.Drug) 